desmoid tumors

Ask MedXY AI

Latest news

Tag

$Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights$

newsclinical trialdesmoid tumors

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

By MedXY|Jan 13, 2026

This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise

Hematology-Oncologydesmoid tumors

Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile

By MedXY|Dec 8, 2025

Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable